Wednesday, December 7, 2022, 7:00 PM – 9:00 PM Central Time (8:00 PM – 10:00 PM Eastern Time) – San Antonio, Texas

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast Cancer (Part 1 of a 2-Part Series)

A CME Satellite Symposium Held in Conjunction with the 2022 San Antonio Breast Cancer Symposium®

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room
To be announced


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Erika Hamilton, MD
Director, Breast and Gynecologic Research Program
Sarah Cannon Research Institute/Tennessee Oncology
Nashville, Tennessee

Sara A Hurvitz, MD
Professor of Medicine
Director, Breast Cancer Clinical Trials Program, Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Medical Director, Clinical Research Unit
Jonsson Comprehensive Cancer Center
Santa Monica, California

Ian E Krop, MD, PhD
Associate Director, Clinical Research
Director, Clinical Trials Office
Chief Clinical Research Officer
Yale Cancer Center
New Haven, Connecticut


Shanu Modi, MD
Member and Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Sara M Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director, Susan F Smith Center for Women's Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Puma Biotechnology Inc, and Seagen Inc.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Optimizing the Management of Localized HER2-Positive Breast Cancer

  • Key clinical factors in the selection of neoadjuvant and adjuvant systemic therapy for HER2-positive localized breast cancer
  • Available data from clinical trials exploring the feasibility of chemotherapy de-escalation in the setting of dual HER2 blockade for localized disease (eg, ADAPT HER2+/HR-, TRAIN-2)
  • Key data supporting the use of adjuvant T-DM1 for HER2-positive breast cancer; current nonresearch role, if any, for patients beyond those with residual disease after neoadjuvant therapy
  • Patient selection for and clinical factors guiding the use of neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence observed after long-term follow-up of the Phase III ExteNET study
  • Dose escalation and other available strategies to reduce the toxicities associated with postadjuvant neratinib

MODULE 2: Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) without CNS Involvement

  • Clinical factors in the selection and sequencing of therapy for patients with HER2-positive mBC (eg, prior HER2-directed therapy, symptomatology, disease-free interval, sites of metastases, HR status)
  • Key efficacy and safety findings from the Phase III DESTINY-Breast03 trial evaluating trastuzumab deruxtecan (T-DXd) versus T-DM1 for HER2-positive mBC previously treated with trastuzumab and a taxane; recent FDA approval of T-DXd in this setting
  • Outcomes observed with T-DXd for HER2-low mBC in the Phase III DESTINY-Breast04 study; recent FDA approval and implications for clinical practice
  • Available efficacy and safety findings from the pivotal HER2CLIMB, DESTINY-Breast01 and NALA studies of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine, respectively, for previously treated HER2-positive mBC
  • Optimal integration of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine into therapy for patients with HER2-positive mBC without brain metastases

MODULE 3: Influence of HER2-Positive Brain Metastases on Therapeutic Decision-Making

  • Incidence of CNS metastases in patients with HER2-positive mBC and effect on overall prognosis
  • Appropriate management of HER2-positive disease progression that is limited to the CNS; utility of local strategies
  • Comparative levels of CNS penetration of approved agents for HER2-positive breast cancer
  • Antitumor activity of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine in patients with brain metastases
  • Ongoing clinical trials (eg, TUXEDO-1, HER2CLIMB-04) attempting to further establish the role of novel HER2-directed therapies for patients with brain metastases

MODULE 4: Future Directions in the Management of HER2-Positive Localized and Metastatic Breast Cancer

  • Scientific rationale for ongoing clinical trials (eg, DESTINYBreast05, CompassHER2 RD) assessing novel HER2-targeted strategies (eg, tucatinib/T-DM1, T-DXd) for HER2-positive localized breast cancer; estimated study completion dates
  • Design, eligibility criteria, key endpoints and estimated completion date of the Phase III HER2CLIMB-02 study of tucatinib or placebo in combination with T-DM1 for unresectable locally advanced or metastatic HER2-positive breast cancer
  • Other ongoing trials evaluating tucatinib for HER2-positive mBC (eg, HER2CLIMB-04 and 05)
  • Early results with T-DXd in combination with other systemic anticancer therapies for HER2-positive mBC; ongoing trials (eg, DESTINY-Breast07, DESTINY-Breast09)
  • Other promising agents and strategies for localized and advanced HER2-positive breast cancer

MODULE 5: Incidence and Management of Adverse Events (AEs) Associated with HER2-Targeted Therapy

  • Optimal prophylactic approaches to mitigating neratinib-associated gastrointestinal (GI) toxicities
  • Practical implementation of neratinib postadjuvant therapy; initial dosing and rationale for dose escalation
  • Incidence of interstitial lung disease observed with T-DXd; recommendations for monitoring, management and discontinuation
  • Spectrum, incidence, severity and management of other toxicities reported with T-DXd
  • Frequency, severity and management of GI toxicity and other clinically relevant AEs associated with tucatinib

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the key clinical variables that affect the use of preoperative therapy and the selection of a specific neoadjuvant therapeutic regimen for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Apply available research evidence to individualize the selection and use of adjuvant systemic therapy for patients with HER2-positive localized breast cancer who received neoadjuvant treatment.
  • Evaluate published research data to guide the selection and duration of adjuvant and extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Implement a long-term clinical plan for the management of advanced HER2-positive breast cancer, considering recently presented clinical research and incorporating available and recently approved targeted agents and regimens.
  • Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior therapeutic exposure, symptomatology and other factors.
  • Recognize common and rare side effects associated with existing and recently approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Puma Biotechnology Inc, and Seagen Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
To be announced

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center where the 2022 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast cancer surgeons, nurses, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this hybrid event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Registration for this event is separate from the 2022 San Antonio Breast Cancer Symposium.
​ ​
IN-PERSON registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

In-Person Registration for clinicians in practice »
 
IN-PERSON registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

In-Person Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.